Although increased osteoclastic bone resorption is the mechanism responsible for bone loss in the postmenopausal period, in malignant diseases which involve the skeleton and Paget's disease, the molecular mechanisms responsible for osteoclastic bone resorption remain unclear. Recently, new light has been shed on this process with the observation that expression of the src proto-oncogene (pp6Ocsrc) is required (and essential) for normal osteoclastic bone resorption. This was shown unexpectedly in transgenic mice deficient in src expression and produced by the technique of introducing the null mutation into the gene by homologous recombination. Our plan In this application is to examine the mechanisms responsible for this impaired osteoclast function using in vitro and in vivo techniques in src deficient (src-) and normal wild type mice. We plan to determine whether src expression is required for osteoclast formation, or activation of cells already formed, or both. To evaluate this question, we plan to culture bone marrow cells and spleen cells from homozygous src deficient mutants. We also plan to determine whether the osteopetrosis is due to a microenvironmental defect or to a defect in cells in the osteoclast lineage. Two approaches will be utilized in these experiments. In one approach, experiments are currently being performed by Dr. Soriano using transplants of fetal liver cells to lethally irradiated recipients. In a second approach, we will perform experiments in vitro using spleen cells or bone marrow cells (as a source of osteoclast precursors) co-cultured with stromal cells which are obtained either from cultures from the marrow cavity or from freshly isolated calvarial cells. These experiments should allow us to determine whether src expression is required in cells in the osteoclast lineage or the accessory cells involved in bone resorption. We also plan to examine the effects of inhibitors of src tyrosine kinase on osteoclastic bone resorption both in vitro and in vivo. We have a number of inhibitors available to us, one of which preferentially inhibits src tyrosine kinase. In addition, we plan to examine the effects of parathyroid hormone and other stimulators of bone resorption on the expression of tyrosine kinase activity, the phosphorylated substrate of tyrosine kinase, and src expression in isolated osteoclasts, osteoblasts, and accessory cells associated with bone resorption. These experiments should enable us to determine a) whether the requirement for src expression is in the osteoclast lineage or in accessory cells; b) whether src expression is required for formation of osteoclasts, or for their activation; c) whether PTH exerts its effects on bone resorption to enhance expression of src tyrosine kinase; and d) exploration of the potential of novel approaches of inhibiting bone resorption both in vitro and in vivo.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK045229-02
Application #
3246749
Study Section
Arthritis and Musculoskeletal and Skin Diseases Special Grants Review Committee (AMS)
Project Start
1992-02-01
Project End
1996-01-31
Budget Start
1993-02-01
Budget End
1994-01-31
Support Year
2
Fiscal Year
1993
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Hiraga, Toru; Myoui, Akira; Hashimoto, Nobuyuki et al. (2012) Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res 72:4238-49
Yoneda, Toshiyuki; Hashimoto, Nobuyuki; Hiraga, Toru (2004) Bisphosphonate actions on bone and visceral metastases. Cancer Treat Res 118:213-29
Hiraga, Toru; Williams, Paul J; Ueda, Akimi et al. (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10:4559-67
Mori, Yoshihisa; Shimizu, Nobuaki; Dallas, Mark et al. (2004) Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104:2149-54
Myoui, Akira; Nishimura, Riko; Williams, Paul J et al. (2003) C-SRC tyrosine kinase activity is associated with tumor colonization in bone and lung in an animal model of human breast cancer metastasis. Cancer Res 63:5028-33
Nishimura, Riko; Hata, Kenji; Ikeda, Fumiyo et al. (2003) The role of Smads in BMP signaling. Front Biosci 8:s275-84
Hata, Kenji; Nishimura, Riko; Ikeda, Fumiyo et al. (2003) Differential roles of Smad1 and p38 kinase in regulation of peroxisome proliferator-activating receptor gamma during bone morphogenetic protein 2-induced adipogenesis. Mol Biol Cell 14:545-55
Michigami, Toshimi; Hiraga, Toru; Williams, Paul J et al. (2002) The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Res Treat 75:249-58
Nishimura, R; Hata, K; Harris, S E et al. (2002) Core-binding factor alpha 1 (Cbfa1) induces osteoblastic differentiation of C2C12 cells without interactions with Smad1 and Smad5. Bone 31:303-12
Yi, Bing; Williams, Paul J; Niewolna, Marie et al. (2002) Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62:917-23

Showing the most recent 10 out of 28 publications